AU2014277981B2 - Compositions and methods of immunizing against C. difficile - Google Patents

Compositions and methods of immunizing against C. difficile Download PDF

Info

Publication number
AU2014277981B2
AU2014277981B2 AU2014277981A AU2014277981A AU2014277981B2 AU 2014277981 B2 AU2014277981 B2 AU 2014277981B2 AU 2014277981 A AU2014277981 A AU 2014277981A AU 2014277981 A AU2014277981 A AU 2014277981A AU 2014277981 B2 AU2014277981 B2 AU 2014277981B2
Authority
AU
Australia
Prior art keywords
day
administration
days
difficile
toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014277981A
Other languages
English (en)
Other versions
AU2014277981A1 (en
Inventor
Guy DE BRUYN
Ginamarie FOGLIA
Sanjay Gurunathan
Patricia PIETROBON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51168412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014277981(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of AU2014277981A1 publication Critical patent/AU2014277981A1/en
Application granted granted Critical
Publication of AU2014277981B2 publication Critical patent/AU2014277981B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2014277981A 2013-06-14 2014-06-13 Compositions and methods of immunizing against C. difficile Ceased AU2014277981B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361835246P 2013-06-14 2013-06-14
US61/835,246 2013-06-14
PCT/US2014/042298 WO2014201346A1 (en) 2013-06-14 2014-06-13 Compositions and methods of immunizing against c. difficile

Publications (2)

Publication Number Publication Date
AU2014277981A1 AU2014277981A1 (en) 2016-01-07
AU2014277981B2 true AU2014277981B2 (en) 2019-06-20

Family

ID=51168412

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014277981A Ceased AU2014277981B2 (en) 2013-06-14 2014-06-13 Compositions and methods of immunizing against C. difficile

Country Status (12)

Country Link
US (4) US9730994B2 (enExample)
EP (1) EP3007724B1 (enExample)
JP (1) JP6691477B2 (enExample)
KR (1) KR20160020543A (enExample)
CN (1) CN105611942A (enExample)
AU (1) AU2014277981B2 (enExample)
BR (1) BR112015031088A2 (enExample)
CA (1) CA2915279A1 (enExample)
MX (1) MX2015017257A (enExample)
SG (1) SG11201510166YA (enExample)
TW (1) TWI648063B (enExample)
WO (1) WO2014201346A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2969952T3 (es) 2011-04-22 2024-05-23 Wyeth Llc Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN105611942A (zh) 2013-06-14 2016-05-25 圣诺菲·帕斯图尔公司 针对艰难梭菌免疫的组合物和方法
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2019064115A1 (en) * 2017-09-28 2019-04-04 Pfizer Inc. COMPOSITIONS AND METHODS FOR GENERATING A DIFFICULT CLOSTRIDIUM IMMUNE RESPONSE
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020304A1 (en) * 1997-10-20 1999-04-29 Oravax, Inc. Passive immunization against clostridium difficile disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071759A (en) 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP2198007B1 (en) * 2007-09-14 2017-10-25 Sanofi Pasteur Biologics, LLC Pharmaceutical compositions containing clostridium difficile toxoids a and b
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
ES2969952T3 (es) 2011-04-22 2024-05-23 Wyeth Llc Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
JP2016516721A (ja) 2013-03-15 2016-06-09 サノフィ パストゥール インコーポレイテッド トキソイド、組成物および関連方法
US20160030542A1 (en) 2013-03-15 2016-02-04 Sanofi Pasteur, Inc. Toxoid, Compositions and Related Methods
CN105611942A (zh) 2013-06-14 2016-05-25 圣诺菲·帕斯图尔公司 针对艰难梭菌免疫的组合物和方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020304A1 (en) * 1997-10-20 1999-04-29 Oravax, Inc. Passive immunization against clostridium difficile disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GINAMARIE FOGLIA ET AL, "Clostridium difficile: Development of a novel candidate vaccine", VACCINE, (2012-06-01), vol. 30, no. 29, doi:10.1016/j.vaccine.2012.01.056, ISSN 0264-410X, pages 4307 - 4309 *
GREENBERG RICHARD N ET AL, "Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine.", VACCINE 16 MAR 2012, (2012-03-16), vol. 30, no. 13, ISSN 1873-2518, pages 2245 - 2249 *
KOTLOFF K ET AL, "Safety and immunogenicity of increasing doses of a clostridium difficile toxoid administrated to healthy adults", INFECTION AND IMMUNITY, (2001-02-01), vol. 69, no. 2, pages 988 - 995 *

Also Published As

Publication number Publication date
US20200113991A1 (en) 2020-04-16
WO2014201346A1 (en) 2014-12-18
CA2915279A1 (en) 2014-12-18
BR112015031088A2 (pt) 2017-07-25
MX2015017257A (es) 2016-11-11
TWI648063B (zh) 2019-01-21
CN105611942A (zh) 2016-05-25
US20210145956A1 (en) 2021-05-20
US11419930B2 (en) 2022-08-23
AU2014277981A1 (en) 2016-01-07
US20160120968A1 (en) 2016-05-05
US9730994B2 (en) 2017-08-15
EP3007724B1 (en) 2023-07-05
EP3007724A1 (en) 2016-04-20
SG11201510166YA (en) 2016-01-28
KR20160020543A (ko) 2016-02-23
JP2016521754A (ja) 2016-07-25
TW201536314A (zh) 2015-10-01
JP6691477B2 (ja) 2020-04-28
US20170304423A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
US11419930B2 (en) Compositions and methods for immunizing against C. difficile
Enioutina et al. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity
US20250312432A1 (en) Compositions and methods for eliciting an immune response against clostridium difficile
RU2559782C2 (ru) Набор для детекции спор, происходящих из микобактерий
RU2648842C2 (ru) Липосомный препарат, предназначенный для лечения или предупреждения туберкулеза
JP2019065001A (ja) クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）に対する免疫応答を惹起するための組成物および方法
TW202438104A (zh) 誘發針對困難梭狀芽孢桿菌之免疫反應的免疫原性組成物和方法
US20080241190A1 (en) Vaccination of horses against lawsonia intracellularis
Jarosova et al. Effects of oil-based adjuvants on the immune response of pigs after dermal administration of antigen and evaluation of the immunization level after a subsequent Actinobacillus pleuropneumoniae challenge in pigs
JP7399865B2 (ja) 哺乳動物における趾皮膚炎に使用されるワクチン組成物
US20210220459A1 (en) Vaccine compositions
CA3082608C (en) Vaccine compositions for use against digital dermatitis in a mammal
WO2019081583A1 (en) VACCINE AGAINST SINGLE STEM DYSENTERY
TW202612726A (zh) 誘發針對困難梭狀芽孢桿菌的免疫反應之免疫原性組成物和方法
AU776364B2 (en) Veterinary vaccines
TW201016231A (en) Lawsonia intracellularis bacterium of a novel serotype, vaccine based on that bacterium, antibodies suitable for diagnosing the novel Lawsonia intracellularis serotype and hybridomas for producing the said antibodies
Sunita et al. Improved humoral immune response in sheep against epsilon toxoid following co-adjuvantation with gel and water in oil formulation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired